COMBINED MIRTAZAPINE AND SSRI TREATMENT OF PTSD: A PLACEBO-CONTROLLED TRIAL: Research Article: Mirtazapine and SSRI Treatment of PTSD
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Combined treatment with a selective serotonin reuptake inhibitor (SSRI) plus mirtazapine has shown superior efficacy in some studies of depression, but has not been studied in posttraumatic stress disorder (PTSD). This study aimed to assess acceptability of combined sertraline plus mirtazapine treatment for PTSD and to estimate its effect size relative to sertraline plus placebo. METHODS: Thirty-six adults with PTSD were randomized to 24 weeks of double-blind treatment with sertraline plus mirtazapine or sertraline plus placebo. Outcomes were analyzed with mixed effects models. RESULTS: The combined treatment group showed a significantly greater remission rate (P = .042) and improvement in depressive symptoms (P = .023) than the sertraline plus placebo group. There were no significant group differences in the two primary outcomes of treatment retention and PTSD severity, or in other secondary outcomes (sleep impairment, sexual functioning, quality of life, and physical and mental functioning), but the combined treatment group showed numerical advantages on all of these outcomes, and effect sizes relative to sertraline plus placebo ranged from small to moderate (d = .26-.63). Both treatments were well-tolerated, with significantly increased appetite but not weight gain in the combined treatment group. CONCLUSION: Findings suggest that combined treatment of PTSD with sertraline plus mirtazapine may have clinically meaningful advantages in symptomatic improvement, relative to SSRI treatment alone, and acceptable tolerability. Combined treatment with an SSRI plus mirtazapine in PTSD deserves additional study as initial treatment or as an augmentation strategy for nonresponders to an SSRI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fitzmaurice, G. M., Laird, N. M., & Ware, J. H. (2011) · Wiley Series in Probability and Statistics · doi:10.1002/9781119513469 · Cited by 4,639
Post-traumatic stress disorder following disasters: a systematic review
Neria, Y., Nandi, A., & Galea, S. (2008) · Psychological Medicine · doi:10.1017/s0033291707001353 · Cited by 1,429 · cited 1×
“[1] PTSD develops in over 15% of persons who have been exposed to a traumatic event,[2] and risk factors may include Hispanic ethnicity or other minority status.[3, 4] Sufferers experience high comorbidity with mood, anxiety, and substance use disorders,[1, 5] and an increased risk of suicide,[6, 7] as well as interpe…”
BackgroundSelf-citationIntrusive re‐experiencing in post‐traumatic stress disorder: Phenomenology, theory, and therapy
Ehlers, A., Hackmann, A., & Michael, T. (2004) · Memory · doi:10.1080/09658210444000025 · Cited by 645
Pharmacotherapy for post traumatic stress disorder (PTSD)
Stein, D. J., Ipser, J. C., Seedat, S., Sager, C., & Amos, T. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002795.pub2 · Cited by 519
Blier, P., Ward, H. E., Tremblay, P., Laberge, L., Hébert, C., & Bergeron, R. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09020186 · Cited by 316 · cited 2×
“[39] The findings here of advantages in efficacy for mirtazapine plus sertraline, and specifically for depressive symptoms, are consistent with two small RCTs of treatment with mirtazapine combined with an SSRI or SNRI for MDD,[19, 20] but they differ from the larger COMED trial in MDD, which reported thoroughly null…”
ResultEtiology of depression comorbidity in combat-related PTSD: a review of the literature
Stander, V. A., Thomsen, C. J., & Highfill-McRoy, R. M. (2014) · Clinical Psychology Review · doi:10.1016/j.cpr.2013.12.002 · Cited by 271 · cited 1×
“Depression is extremely common in PTSD, due to both the likely influence of common etiologic factors, and PTSD being a risk factor for secondary depression.[38] This overlap of PTSD and depression is reflected in the recent addition of a criterion for negative cognitions and mood for the diagnosis of PTSD in DSM-5.”
BackgroundA double-blind, placebo-controlled study of antidepressant augementation with mirtazapine
Carpenter, L. L., Yasmin, S., & Price, L. H. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01262-8 · Cited by 244
Marshall, R. D., Lewis-Fernandez, R., Blanco, C., Simpson, H. B., Lin, S.-H., Vermes, D., Garcia, W., Schneier, F., Neria, Y., Sanchez-Lacay, A., et al. (2007) · Depression and Anxiety · doi:10.1002/da.20176 · Cited by 98 · cited 2×
“[10–12] These limitations may contribute to substantial dropout rates of over 30% in PTSD sertraline trials[12, 13] and PTSD pharmacotherapy trials in general,[14] and reduced likelihood of receiving the longer term SSRI treatment that has been associated with higher rates of response.[15, 16] More efficacious treatme…”
BackgroundMethodSelf-citation
Cited by
Hoskins, M. D., Bridges, J., Sinnerton, R., Nakamura, A., Underwood, J. F. G., Slater, A., Lee, M. R. D., Clarke, L., Lewis, C., Roberts, N. P., et al. (2021) · European Journal of Psychotraumatology · doi:10.1080/20008198.2020.1802920 · Cited by 127
“…(Becker et al., 2007), eszopiclone (Pollack et al., 2011), guanfacine (Neylan et al., 2006), hydrocortisone (Ludascher et al., 2015), mirtazapine (Schneier et al., 2015), nabilone (Jetly et al., 2015), olanzapine (Stein et al., 2002), pregabalin (Baniasadi et al., 2014), sodium valproate (Hamner…”
BackgroundInfluentialRyan, J., Chaudieu, I., Ancelin, M.-L., & Saffery, R. (2016) · Epigenomics · doi:10.2217/epi-2016-0083 · Cited by 85
Treatment of posttraumatic stress disorder: Focus on pharmacotherapy
Ehret, M. (2019) · Mental Health Clinician · doi:10.9740/mhc.2019.11.373 · Cited by 53
Bajor, L. A., Balsara, C., & Osser, D. N. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114840 · Cited by 43
Metadata
- Authors
- Schneier, F. R., Campeas, R., Carcamo, J., Glass, A., Lewis-Fernandez, R., Neria, Y., Sanchez-Lacay, A., Vermes, D., & Wall, M. M.
- Venue
- Depression and Anxiety
- Publisher
- Wiley
- Published
- 2015-06-26
- Volume
- 32
- Issue
- 8
- Pages
- 570-579
- ISSN
- 1091-4269 (ISSN-L)
- OpenAlex
- W1959427819
- Cited by
- 61
- References
- 8
- FWCI
- 6.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.